Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
The Motley Fool April 27, 2010 Brian Orelli	Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home.
The Motley Fool June 25, 2008 Brian Orelli	WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play?
The Motley Fool May 30, 2008 Brian Orelli	WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool March 14, 2008 Brian Orelli	No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company.
The Motley Fool June 15, 2006 Brian Gorman	Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool January 25, 2007 Brian Gorman	Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
The Motley Fool January 27, 2006 Brian Gorman	Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet.
The Motley Fool April 28, 2006 Brian Gorman	Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note.
The Motley Fool August 9, 2006 Brian Gorman	Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note.
The Motley Fool October 30, 2006 Brian Gorman	Quality in Covance Some investors are pulling back from the company's stock, but Covance will continue to deliver.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
The Motley Fool May 10, 2006 Brian Gorman	Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool November 7, 2006 Brian Gorman	Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note.
The Motley Fool May 4, 2005 Brian Gorman	Relaxing on the River Charles River Laboratories' full suite of services looks like a winning concept.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
Pharmaceutical Executive December 1, 2012 Torrey et al.	Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.
The Motley Fool October 21, 2005 Brian Gorman	Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
The Motley Fool April 25, 2005 Brian Gorman	Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar.
The Motley Fool January 29, 2009	Today's 5-Star Movers Today's list of top-moving stocks from the Motley Fool five-star stock list.
The Motley Fool July 22, 2011	Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again.
The Motley Fool October 29, 2009 Robert Steyer	Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle.
The Motley Fool August 25, 2006 Brian Gorman	California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely.
Bio-IT World October 14, 2004 Michael Greeley	Go East Business is great in China, and the government is strongly encouraging the local biotech industry.